Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

By sjmartinez • February 24, 2023

Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ, Zook M, Lee M, Zou L, Jiang GL, Paolini JF. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023 Feb 3;57:101826. doi: 10.1016/j.eclinm.2023.101826. PMID: 36816342; PMCID: PMC9932343.

Tags: Dermatology, Olive View DoM, Publications

AI-Assisted Billing in Dermatologic Surgery: Evaluating ChatGPT’s and Gemini’s Accuracy in CPT Code Assignment

Modiri O, Ebriani J, Jairath N, Lewin J. AI-Assisted Billing in Dermatologic Surgery: Evaluating ChatGPT's and Gemini's Accuracy in CPT Code Assignment. Dermatol Surg. 2025[...]

Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification

Strober B, Patel M, Kaldas MI, St John G, Photowala H, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-World Skin Clearance and Quality of[...]

The Epidemiology of Atopic Dermatitis Among Adults and Adolescents with Alopecia Areata in the United States

Bunick CG, Armstrong AW, Grada A, Soliman AM, Li C, Bristow CC, Khan IA, Lipiszko D, Silverberg JI, Issa NT, Mostaghimi A. The Epidemiology of[...]